Abstract
Peroxisome proliferator-activated receptor-γ (PPAR-γ) belongs to a family of ligand-activated nuclear receptor and transcription factors. The essential roles of PPAR-γ in controlling metabolic processes have been underscored by the successful use of PPAR-γ agonists thiazolidinediones to treat insulin resistance, a central feature of metabolic syndrome. PPAR-γ is also expressed in the vascular tissues including endothelial cells (ECs), smooth muscle cells (SMCs) and macrophages. Increasing evidence suggests that PPAR-γ is implicated both in the maintenance of vascular homeostasis and in the pathogenesis of a number of vascular conditions such as atherosclerosis, hypertension and restenosis. As an important regulator of vascular biology, PPAR-γ may represent a potential therapeutic target for these metabolic vascular disorders. This review will focus on the recent advances related to the biological functions of PPAR-γ in various vascular processes as well as the significances of the pharmacological activators/modulators of this metabolic nuclear receptor in vascular disorders.
Keywords: Peroxisome proliferator-activated receptor, thiazolidinediones, metabolic syndrome, cardiovascular risk, diabetes
Cardiovascular & Hematological Disorders-Drug Targets
Title: Peroxisome Proliferator-Activated Receptor-γ in Vascular Biology
Volume: 7 Issue: 2
Author(s): Jingjue Li and Nanping Wang
Affiliation:
Keywords: Peroxisome proliferator-activated receptor, thiazolidinediones, metabolic syndrome, cardiovascular risk, diabetes
Abstract: Peroxisome proliferator-activated receptor-γ (PPAR-γ) belongs to a family of ligand-activated nuclear receptor and transcription factors. The essential roles of PPAR-γ in controlling metabolic processes have been underscored by the successful use of PPAR-γ agonists thiazolidinediones to treat insulin resistance, a central feature of metabolic syndrome. PPAR-γ is also expressed in the vascular tissues including endothelial cells (ECs), smooth muscle cells (SMCs) and macrophages. Increasing evidence suggests that PPAR-γ is implicated both in the maintenance of vascular homeostasis and in the pathogenesis of a number of vascular conditions such as atherosclerosis, hypertension and restenosis. As an important regulator of vascular biology, PPAR-γ may represent a potential therapeutic target for these metabolic vascular disorders. This review will focus on the recent advances related to the biological functions of PPAR-γ in various vascular processes as well as the significances of the pharmacological activators/modulators of this metabolic nuclear receptor in vascular disorders.
Export Options
About this article
Cite this article as:
Li Jingjue and Wang Nanping, Peroxisome Proliferator-Activated Receptor-γ in Vascular Biology, Cardiovascular & Hematological Disorders-Drug Targets 2007; 7 (2) . https://dx.doi.org/10.2174/187152907780830932
DOI https://dx.doi.org/10.2174/187152907780830932 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Updated Electrocardiographic Classification of Acute Coronary Syndromes
Current Cardiology Reviews Chronic Obstructive Pulmonary Disease and Sleep Disordered Breathing - The Overlap Syndrome: An Evolving Clinical Phenotype
Current Respiratory Medicine Reviews Human Cognitive and Neuro-Psychiatric Bio-Markers in the Cardiac Peri-Operative Patient
Current Molecular Medicine Effects of Remifentanil on the Cardiac Conduction System. Our Experience in the Study of Remifentanil Electrophysiological Properties
Current Pharmaceutical Design Pharmacological Potential of Exercise and RAS Vasoactive Peptides for Prevention of Diseases
Current Protein & Peptide Science Regulatory Mechanism of the Gastric Hyperemic Response Following Barrier Disruption: Roles of Cyclooxygenase-1, the Prostaglandin E<sub>2</sub>/EP1 Receptor and Sensory Neurons
Current Pharmaceutical Design Reactions of 4-(Diethylamino)selenet-2(2H)-imine with Nucleophiles – Synthesis of 2-Methylen-3-oxobutane Selenoamides
Letters in Organic Chemistry Autophagy Inhibition Rescues Against Leptin-Induced Cardiac Contractile Dysfunction
Current Pharmaceutical Design PDE5 Inhibitor Treatment Options for Urologic and Non-Urologic Indications: 2012 Update
Current Pharmaceutical Design What Restricts the Clinical Use of Nicotinic Acid?
Current Vascular Pharmacology New Advances in Blockade of the Renin-Angiotensin System – the Role of Direct Renin Inhibition
Current Hypertension Reviews Metabolic Syndrome Targets
Current Drug Targets - CNS & Neurological Disorders Antiarrhythmic Therapy on Prevention of Postoperative Atrial Fibrillation in Patients After Heart Surgery
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Effects of Estrogens on Atherogenesis
Current Vascular Pharmacology Mycophenolate Mofetil for the Treatment of Systemic Sclerosis
Letters in Drug Design & Discovery The Effect of Local Alcohol Delivery in Reducing Intimal Hyperplasia Induced by Vascular Injury and the Clinical Implications
Vascular Disease Prevention (Discontinued) Cardiovascular Disease in Patients with Chronic Obstructive Pulmonary Disease, Obstructive Sleep Apnoea Syndrome and Overlap Syndrome
Current Vascular Pharmacology A Case of Topiramate-Induced Epistaxis
Current Drug Safety High Throughput Metabolomics in Clinical Studies: Review and New Applications to Remote Ischemic Preconditioning
Current Topics in Medicinal Chemistry Potential Deployment of Angiotensin I Converting Enzyme Inhibitors and of Angiotensin II Type 1 and Type 2 Receptor Blockers in Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry